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AbstrAct
Hypoxia, particularly hypobaric hypoxia, is a multifaceted entity which includes certain molecular, patho-
physiological and biochemical aspects. Any single aspect in itself cannot help us elucidate hypobaric hypoxia in its 
entirety. We observed three crucial lacunae within the existing literature. These include a lack of high-throughput 
investigations into redox PTMs, particularly NO-based PTMs; a prophylactic supplement with proven efficacy 
and safety which doesn’t involve medical supervision and is not contraindicated in hepatic, renal and cardiac 
insufficiencies; and a clinically validated rodent model of HAPE without any genetic/pharmacological manipulations. 
In the present study, we present an antagonistic interplay between nitrosylation and carbonylation which shows 
an additional NO-based network that is active in acclimatised individuals. Then we present a micronised aqueous 
suspension of silymarin which is efficacious at low doses in providing antioxidant, anti-inflammatory and hypoxia-
adaptive vascular responses in addition to being a free radical quencher itself. Silymarin has an excellent safety 
and efficacy profile in humans. Finally, we create a SD rat model of HAPE which was used to reverse-translate 
a previously known HAPE marker in humans (SULT1A1) and elucidate the synergistic occurrence of HAPE and 
inflammation cascades. This is the first radiologically validated rodent HAPE model. In conclusion, we were able 
to elucidate the molecular, biochemical and patho-physiological aspects of hypobaric hypoxia which were left out 
by previous studies.
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1.  IntroDuctIon
Hypobaric hypoxia, the most widespread form of 
environmental hypoxia encountered on this planet has 
fascinated the human psyche since the ancient times. Ancient 
folklore refers to the mountains as God’s abode, a magical 
place with many gifts and pitfalls and a place to seek solitude 
and immortality. Indeed, with the advent of modern science 
and a deeper understanding of the effects of hypobaric hypoxia 
on human physiology, we now know that high altitude 
training is a gift to improve sports performance and tolerance 
to oxygen-deficient conditions in humans. High altitude is 
equally unforgiving in that it causes high altitude illnesses like 
acute mountain sickness (AMS) and high altitude pulmonary 
edema (HAPE) in those who ascend without rest. We have 
also found multiple herbal concoctions at high altitude that not 
only improve general health but also help prevent high altitude 
illnesses.
Our lab has been at the forefront of understanding how 
the proteome responds to hypobaric hypoxia at altitude. The 
proteome simply means collection of all the proteins that are 
present in a given cell/tissue/organ/organism at a particular 
time. As per the definition provided by Wilkins, proteome is 
defined as “the entire complement of proteins expressed by a 
genome, cell, tissue or organism.” The study of the proteome 
is called proteomics. Proteomics has three cornerstones for 
the effective understanding of data and its conversion into 
knowledge. First is fractionation and separation of a sample 
into constituent proteins/peptides; second is its analysis using 
mass spectrometry (MS) (other older methods also may be 
used) and third is use of bioinformatics based network analysis 
tools to find the protein networks being indicated by the proteins 
identified and quantified during MS analysis. As is well known, 
the proteome has much greater complexity as compared to the 
genome of an organism. Also, the proteomic response is a real 
time response to prevalent stimuli while most of the genomic 
response is in the order of years and generations.
Since hypobaric hypoxia occurs with greater intensity and 
over longer durations as we ascend higher, the study of the 
proteome especially during acute and sub-chronic exposures, 
makes sense. In this regard, based on previous studies (of which a 
sizable chunk was contributed by our lab), we identified crucial 
missing links and then investigated these aspects for a better 
understanding of hypobaric hypoxia’s effect on the proteome. 
During previous proteomics based studies1-7, we observed that 
post-translational modifications (PTMs) brought about by 
hypoxia induced redox stress were not actively investigated 
for any sort of association. This is despite the fact that protein 
functions, signalling cascades are profoundly affected by redox 
PTMs.
Secondly, we observed a great emphasis on drug Received : 04 October 2019, Revised : 20 April 2020 
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repurposing during prophylaxis against hypobaric hypoxia. A 
great many drugs were present, including but not limited to, 
nifedipine, salmeterol, budesonide, tadalafil, acetazolamide 
and etc. on the market as prophylactics. However, almost 
all of these drugs were contra-indicated in people with 
cardiovascular, renal and hepatic insufficiencies. They were 
also contra-indicated in pregnant and breastfeeding females8-10. 
Some of these medicines (e.g. salmeterol) are also advised to 
be used with caution in individuals who have had recurrent 
HAPE11. Apart from this, all of these drugs require medical 
supervision for use. The dosage must be strictly adhered to 
and overdosing is an issue. Thus, the requirement for a general 
use health supplement that is not contraindicated in conditions 
like renal and hepatic insufficiencies, doesn’t require medical 
supervision for dosage and can be taken during pregnancy and 
breastfeeding is the need of the hour. Also, this said prophylactic 
must be easy to manufacture and cost-effective.
Finally, we observed that although there was a fair 
understanding of the symptoms and their management in cases 
of high altitude illnesses, particularly HAPE, the underlying 
molecular reasons were yet to be fully elucidated. This lack 
of understanding of HAPE was due to the fact that it affected 
human lungs, which are not easily accessible and there existed 
no clinically validated animal model of HAPE. Hence, we 
strived to investigate solutions to these shortcomings in 
hypoxia research and eliminate them.
2. nItrosylAtIon AnD cArbonylAtIon 
Are InvolveD In A tug-of-wAr wItHIn 
A cell: IMPlIcAtIons for cell fAte 
DurIng HyPoxIA
Nitric oxide (NO) is central to the vasculo-endothelial 
response to hypoxia. It was initially identified as the endothelium 
derived relaxing factor12,13. Human studies focusing on high 
altitude native populations have found higher NO concentration 
as a major distinguishable characteristic during successful 
hypoxia adaptive response14,15. Previous studies show that 
lower exhaled NO is characteristic of maladaptive high 
altitude exposure16-18 and HAPE susceptibility19-21. A previous 
study by Singh22, et al from our lab showed that increased NO 
bioavailability during hypoxia helps activate antioxidant genes 
and control oxidative stress. NO is also crucial in being the 
sole proprietor of nitrosylation, a type of redox PTM where a 
S-nitrosyl group attaches to amino acid residue, particularly 
cysteine (Cys) and induces altered protein function. Also, 
hypoxia exposure induces excess oxidant/free radical 
generation in the organism. Its well known that CO moiety is 
added to proteins upon exposure to oxygen radicals and this 
leads to proteins being rendered inactive. As hypobaric hypoxia 
induces both NO production and free radical generation, it is 
imperative that the effects of nitrosylation and carbonylation 
be studied and their association elucidated.
based on this, we exposed H9c2 cells to hypoxia 
(simulated; 0.5% O2). In addition, to understand if there was 
any effect of nitrosylation on carbonylation and vice-versa, we 
also used L-NAME (2mM), an inhibitor of NO production. We 
observed that L-NAME individually and hypoxia in addition 
to L-NAME were the most successful in inhibiting both NO 
levels and nitrosylation (Fig. 1). This was then observed to 
cause increased carbonylation as compared to control group23. 
To summarize, we observed that blocking NO production 
led to decreased nitrosylation of proteins, increased rOS 
production and carbonylation of proteins, suppression of 
HIF1a (transcriptional master regulator of hypoxia adaptive 
response); Nrf2 (key transcriptional switch for antioxidant 
response) and gPx3 (central antioxidant) expression as well as 
thioredoxin reductase 2 activity and increased cell death during 
hypoxia exposure. Thus, we observed that nitrosylation and 
carbonylation are antagonistic even though both are triggered 
by hypoxia and reduced nitrosylation usually leads to poorer 
outcomes during hypoxia exposure at the cellular level.
3. MIcronIseD sIlyMArIn HelPs sD rAts 
survIve extreMe HyPobArIc HyPoxIA 
by AugMentIng AntIoxIDAnt AnD 
ADAPtIve vAsculAr resPonses
In the next phase of our study, we wished to propose 
relevant prophylaxis options that were cost-effective, extremely 
safe to use without medical supervision, did not require 
complex formulations and were not contraindicated in cases of 
cardiac, renal and hepatic insufficiencies.
Since such a profile is usually found in herbal formulations, 
we began to search for a suitable herbal prophylactic. The milk 
thistle is a medium sized plant known to be abundant in a wide 
geographical area. It has been characterised since the times 
of Ptolemy as a general health supplement which was later 
proven to be effective against Amanita mushroom poisoning. 
In the present era, its extract (present in leaves, buds, flowers 
and seeds) is a widely sold herbal hepato-protectant and 
general health supplement named silymarin. Silymarin is 
proven to be safe for use in humans, has negligible side-effects 
and a practically unattainable LD
50
. Its is a polyflavonolignan 
mixture comprising multiple constituents with polyphenolic 
and flavonoid rings suggesting excellent radical quenching 
capabilities. It is not contra-indicated in cases of renal and 
cardiac insufficiencies instead it’s use is promoted in such cases. 
However, silymarin has its fair share of issues. Its polyphenolic 
ring structure makes its bioavailability low which is improved 
using complex formulations24-27 that add both dosage intensity 
and cost to an otherwise cost-effective remedy. This drawback 
has impeded its use in general life as life becomes more and 
more hectic.
To improve upon this, we micronised silymarin using 
sonication and filtration in an aqueous solution (PbS). This led 
to a smaller median particle size as well as greater stability 
of the aqueous suspension as compared to the non-sonicated 
silymarin extract in aqueous suspension. The use of micronised 
silymarin also led to greater bioavailability as compared to the 
non-sonicated silymarin suspension. Further, we observed 
that sonicated silymarin suspension upon dosing for 5 days 
at 50 mg/kg bodyweight in SD rats who were subsequently 
exposed to hypobaric hypoxia (simulated; 7620 m for 6 h) 
resulted in reduced rOS and its byproducts like carbonyl 
content; increased antioxidant (glutathione, catalase, SOD etc.) 
expression and activity (Fig. 2); upregulated HIF1a, VEgF 
(improves vascularisation) and EPO (improves hematocrit) 
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figure 1. comparison of trend of carbonylation and nitrosylation: (a) using a coomassie stained gel as loading control, oxy-blots 
and nitroblots assessing carbonylated and nitrosylated proteins (3-D density maps) across normoxia, normoxia+l-nAMe, 
Hypoxia and l-nAMe+Hypoxia groups (Mean±seM), (b) relative trendlines for nitrosylation and carbonylation. each 
data point per group represents percent nitrosylation/carbonylation (derived from Mean±seM of 3-D density maps for both 
nitroblots and oxyblots), and (c) bar-graphs comparing fold-change in protein carbonylation and nitration. elIsA was used 
to determine levels of nitration and carbonylation (Mean±seM). * represents p-value<0.05. # represents p-value<0.01.
(a)
(b) (c)
figure 2. status of key antioxidants: (a) superoxide dismutase (soD), (b) catalase in normoxia, Hypoxia, sMn+Hypoxia and sMn 
groups, (c) representative immunoblots of catalase and soD in normoxia, Hypoxia, sMn+Hypoxia and sMn along with 
bar graphs depicting their respective levels across experimental groups. tubulin was used as loading control, and (d) bar 
graph depicting reduced glutathione concentrations across experimental groups. Significance represented as *p-value<0.05; 
**p-value<0.01. results represented as Mean±seM.
(a) (b)
(c) (d)
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Figure 3. SMN prevented loss of liver function and ameliorated inflammatory response in hypoxia: (a) Representative lung tissue 
sections of normoxia, Hypoxia, sMn+Hypoxia and sMn groups stained with hematoxylin and eosin to visualize qualitative 
inflammatory changes, (b) Fold change across experimental groups in plasma concentrations of cytokines TGF- beta, IL-6 
and tnf-alpha represented as bar-graphs, (c) bar-graph depicting fold change in 8-isoprostanes’ concentration in plasma 
across experimental groups, and (d) FACS analysis of bronchoalveolar lavage fluid of Normoxia (Control); Hypoxia and 




at both transcript and protein levels and also helped diffuse 
hypoxia induced inflammation via repression of cytokines like 
TgF-beta, IL-6 and TNF-alpha28 (Fig. 3). Thus, we created a 
cost-effective micronised silymarin solution that is already 
proven to be safe-for-use in humans and doesn’t require 
medical supervision for use effective at mitigating acute 
hypoxia induced damage.
4. A clInIcAlly vAlIDAteD sD rAt MoDel 
of HAPe
In the third phase of our study, we wanted to create a 
clinically validated HAPE model using SD rats. Our previous 
study had already revealed that the proteome response to 
hypoxia of SD rats and humans share a lot of homology29. 
Thus, we chose the SD rat as our model. In previous 
studies attempting to model HAPE using animals, long 
effort-intensive, equipment-intensive, pharmacological and 
indirect methods to create and confirm HAPE were used30-35. 
Most of these previous studies measured HAPE via ratio of 
wet:dry weight of lung and by estimating the fluid content 
of lungs. Also, the exercise protocols employed were of 
long durations. In a previous study, it has been shown that 
low intensity exercise actually relieves hypertension in rats 
when done over long temporal scales36. Since HAPE has the 
cardinal feature of pulmonary hypertension, the exercise 
protocol is inherently flawed when used for HAPE induction. 
None of these studies attempted establishing HAPE via 
chest x-rays in their models, which is the clinical gold 
standard. None of these previous studies definitively dealt 
with the question of whether HAPE induces inflammation or 
 vice-versa.
In our study, we first exhausted the rat by forcing them 
to swim in a circular tank. At the point of exhaustion, the rats 
were dried off and placed in a hypobaric hypoxia simulation 
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chamber for 18 h at 7620 m. After 18 h, the rats were examined 
using a chest x-ray for signs of edema in the lungs. We 
observed all rats in our swimming+hypoxia group developed 
pulmonary edema. After confirmation of pulmonary edema, 
we harvested the lungs and plasma of the rats. Upon the 
analyses of lungs and plasma, we observed sulfotransferase 
1A1 (SULT 1A1) levels to be the highest in HAPE-afflicted 
rats (Fig. 4). SULT 1A1 was previously reported by our lab to 
be a biomarker for HAPE in humans4. Thus, we successfully 
reverse translated our marker in this study. We also observed 
levels of pro-inflammatory cytokines (e.g. TNF-alpha) to 
increase sharply while dual-role cytokines (e.g. IFN-gamma) 
declined sharply in HAPE-afflicted rats (Figs. 4(b)-4(d)). 
In both cases, hypoxia did not elicit sharp changes in the 
levels of these cytokines. Thus, HAPE and inflammation 
can be termed as synergistic events rather than the cause 
and effect of each other. In addition, H&E staining of lung 
tissues revealed that exudate accumulation only occurred 
in HAPE afflicted lung tissues (Fig. 5). To summarize, our 
study led to a clinically relevant protocol for inducing HAPE 
using which we found that inflammation and HAPE are 
synergistic events37.
5. conclusIon
Our studies revealed that hypoxia exposure causes a 
crosstalk between nitrosylation and carbonylation, adding 
the dimension of PTMs to standard protein response in 
hypoxia. In addition, we were able to provide a novel cost-
effective, prescription-free, side-effect free prophylactic 
choice in silymarin and a clinically validated, reliable and non-
pharmacologic HAPE model for detailed studies on HAPE.
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